Testing how the brain absorbs anti–CD8 therapy in nervous system disease
Part of Brain & nervous system, Immune system & allergy, Infections clinical trials.
This Phase 1 study tests a small drug (called an anti–CD8+ T cell minibody) to see how much reaches the brain. It may help researchers understand how to deliver similar treatments for multiple sclerosis, progressive multifocal leukoencephalopathy (PML), or other brain inflammation when the brain’s protective barrier is “open.”
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and able to consent in writing
- You must be enrolled in the NINDS natural history study for MS, PML, or the PML/MS-adjacent matching track the clinic uses
- You must be willing to follow all study visits for the full study period
- If you are being screened for “open brain barrier” inflammation, you need a recent MRI (within 1 month) showing gadolinium-enhancing areas
- You cannot be pregnant or breastfeeding
- You must be able to have MRI with contrast (gadolinium) and fit in the scanner (weight limit 350 lb / 158 kg)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This pilot study tests an IV medicine called brincidofovir for people with PML, a serious brain infection. The goal is to see if it can stop the virus from causing more damage.
This study looks at how immune-related brain or spinal cord illness shows up using exams, MRI scans, and sometimes a spinal fluid test (lumbar puncture), plus collected blood and other samples. It may help researchers better understand these conditions and improve future diagnosis or treatments.
This study follows people with suspected or confirmed progressive multifocal leukoencephalopathy (PML), people at higher risk, and healthy volunteers. It uses visits, brain imaging (MRI), and stored biological samples to better understand how PML progresses and who is at risk.
This trial tests if pembrolizumab, an immunotherapy drug, can help fight a rare brain virus called PML in people whose immune systems are weakened but not due to HIV. The goal is to see if it improves recovery.
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
This study uses a special PET-MRI scan to look at brain inflammation in people with relapsing-remitting multiple sclerosis (RRMS). It may help researchers understand how inflammation changes when starting a stronger MS treatment.
Hear when a new Progressive Multifocal Leukoencephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.